STANDARD TREATMENT WITH BEVACIZUMAB AS TARGETED THERAPY IN CERVICAL CANCER

被引：0

作者：

Enriquez-Aceves, Isabel ^{[1
]}

Galicia-Carmona, Tatiana ^{[2
,3
]}

Coronel-Martinez, Jaime A. ^{[2
,3
]}

Espinosa-Romero, Raquel ^{[3
]}

Calderillo-Ruiz, German ^{[3
]}

Cortes-Esteban, Patricia ^{[4
]}

Cetina-Perez, Lucely ^{[2
,3
]}

机构：

[1] Hosp Inst Seguridad & Serv Sociales Trabajadores, Dept Med Oncol, Leon, Gto, Mexico

[2] Inst Nacl Cancerol, Dept Clin Res, Mexico City, DF, Mexico

[3] Inst Nacl Cancerol, Dept Med Oncol, Mexico City, DF, Mexico

[4] Ctr Med Nacl 20 Noviembre, Dept Med Oncol, Mexico City, DF, Mexico

来源：

REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION | 2020年 / 72卷 / 04期

关键词：

Bevacizumab; Cervical; Cancer; Metastatic antiangiogenic; PHASE-II TRIAL; SQUAMOUS-CELL-CARCINOMA; COMBINATION THERAPY; 3RD-LINE TREATMENT; OPEN-LABEL; RECURRENT; PERSISTENT; CHEMOTHERAPY; CARBOPLATIN; PACLITAXEL;

D O I：

10.24875/RIC.20000061

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Metastatic, recurrent, or persistent disease in cervical cancer has a poor prognosis. Historically, this group of patients has had limited treatment options, even with the best cytotoxic treatments (platinum-based chemotherapy [CT] doublets). Therefore, investigating new medications that help improve the patient's quality of life and survival has been essential. Angiogenesis has been shown to play a critical role in tumor cell growth and survival. Bevacizumab is a recombinant humanized monoclonal G1 immunoglobulin targeted against vascular endothelial growth factor. The combination of CT and bevacizumab is associated with an increase in overall survival as well as in progression-free survival and response rates.

引用

页码：213 / 218

页数：6

共 50 条

[41] Molecular targeted therapy for the treatment of gastric cancer
Xu, Wenting
Yang, Zhen
Lu, Nonghua
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2016, 35
[42] Bevacizumab Extends Cervical Cancer Survival
McNutt, Marcia
Farrar, Jeremy
Lane, David
CANCER DISCOVERY, 2013, 3 (07) : 709 - 709
[43] Combined targeted therapy and immunotherapy for cancer treatment
Cheng-Xiang Guo
Xing Huang
Jian Xu
Xiao-Zhen Zhang
Yi-Nan Shen
Ting-Bo Liang
Xue-Li Bai
World Journal of Clinical Cases, 2021, (26) : 7643 - 7652
[44] Combined targeted therapy and immunotherapy for cancer treatment
Guo, Cheng-Xiang
Huang, Xing
Xu, Jian
Zhang, Xiao-Zhen
Shen, Yi-Nan
Liang, Ting-Bo
Bai, Xue-Li
WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (26) : 7643 - 7652
[45] Hypertension and targeted therapy Part 1: Bevacizumab
Chowdhury, Simon
Spicer, James F.
Harper, Peter G.
TARGETED ONCOLOGY, 2006, 1 (02) : 104 - 108
[46] Clinical effects of bevacizumab targeted treatment on advanced colorectal cancer with liver metastasis
Lv, W. -H.
Zhao, Y.
Li, X. -D.
Zhang, M. -Q.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2016, 20 (11) : 2249 - 2255
[47] Prospects of Molecularly-Targeted Therapies for Cervical Cancer Treatment
de Freitas, Antonio Carlos
Gomes Leitao, Maria da Conceicao
Coimbra, Eliane Campos
CURRENT DRUG TARGETS, 2015, 16 (01) : 77 - 91
[48] Atezolizumab and Bevacizumab Combination Therapy in the Treatment of Advanced Hepatocellular Cancer
Ventura, Ignacio
Sanchiz, Lorena
Legidos-Garcia, Maria Ester
Murillo-Llorente, Maria Teresa
Perez-Bermejo, Marcelino
CANCERS, 2024, 16 (01)
[49] MOLECULARLY TARGETED TREATMENT WITH ERLOTINIB AND BEVACIZUMAB AS SECOND-LINE TREATMENT FOR INOPERABLE BILIARY CANCER
Jensen, Lars Henrik
Ploen, John
Jakobsen, Anders
ANNALS OF ONCOLOGY, 2012, 23 : 73 - 73
[50] Paclitaxel, Carboplatin, and Bevacizumab in Advanced Cervical Cancer: A Treatment Response and Safety Analysis
Tao, Wanjun
Yang, Jia
Jiang, Yongxian
Chen, Wenwen
Wang, Yixin
DOSE-RESPONSE, 2020, 18 (03):

← 1 2 3 4 5 →